Axcella Health Inc. Common Stock, also called Axcella Health, is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Read More Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA. The listed name for AXLA is Axcella Health Inc. Common Stock.